171 related articles for article (PubMed ID: 36942814)
1. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.
Kunc M; Żemierowska N; Skowronek F; Biernat W
Histopathology; 2023 Jul; 83(1):3-14. PubMed ID: 36942814
[TBL] [Abstract][Full Text] [Related]
2. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
3. PRAME immunohistochemistry of spitzoid neoplasms.
Koh SS; Lau SK; Scapa JV; Cassarino DS
J Cutan Pathol; 2022 Aug; 49(8):709-716. PubMed ID: 35488519
[TBL] [Abstract][Full Text] [Related]
4. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
5. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
6. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
9. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
[TBL] [Abstract][Full Text] [Related]
10. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
11. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
12. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
[TBL] [Abstract][Full Text] [Related]
13. PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms.
Gerami P; Benton S; Zhao J; Zhang B; Lampley N; Roth A; Boutko A; Olivares S; Busam KJ
Am J Dermatopathol; 2022 Aug; 44(8):575-580. PubMed ID: 35503885
[TBL] [Abstract][Full Text] [Related]
14. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
15. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
17. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
19. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
20. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
